Tuberculosis Drug

Tuberculosis Drug Comprehensive Study by Type (First-line Anti-TB Drugs, Second-line Anti-TB Drugs), Application (Active TB, Latent TB), End User (Hospital, Clinic, Durgstore), Testing (TB skin test (TST), TB blood tests, Others) Players and Region - Global Market Outlook to 2026

Tuberculosis Drug Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Tuberculosis remains a global public health concern. According to the World Health Organization, in 2017, the annual incidence of Tuberculosis (TB) in India was 2.8 million cases, with an estimated 147,000 multi-drug resistant cases. India has the second highest estimation of HIV-TB co-infection 87,000 cases per year. The TB treatment drugs market is expected to witness high growth in the coming years due to development of shorter-regimen drug treatments and availability of private and public funding. About one third of the worlds's population is suffering with latent tuberculosis, people infected with mycobacterium infection have a 10% risk to fall ill with tuberculosis, however people with compromised immunity such as HIV, diabetes and tobacco addiction are at a higher risk to get tuberculosis. TB is second to HIV as it is the leading infectious killer of the adults worldwide. Apart from its health consequences, there are many economic impact of the disease which is staggering, making TB a major contributor to poverty.This growth is primarily driven by Increasing Prevalence of Tuberculosis .

AttributesDetails
Study Period2017-2027
Base Year2021
Forecast Period2022-2027
Volume UnitN
Value UnitUSD (Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


The Diseases & Therapeutic Areas sector in the region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Johnson & Johnson (United States), Lupin Limited (India), Pfizer Inc. (United States), Eli Lilly and Company (United States), Labatec Pharma SA (Jordan), Mylan N.V (United States), Sanofi S.A (France), Sandoz S.A (Germany), Novartis International AG (India), Macleods Pharmaceuticals (India) and Otsuka Pharmaceutical Co.Ltd. (Japan), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

The market is fragmented by numerous players. R&D, M&A, product launch are the key strategy adopted in the global tuberculosis diagnosis and treatment market. These players are collaborating with each other for the growth and improvement of the Tuberculosis Drugs market. For instance, In 2017, Johnson & Johnson entered into a partnership with the Institute of Microbial Technology (IMTECH), part of the Council of Scientific and Industrial Research (CSIR), to accelerate the discovery of a novel treatment for tuberculosis.

Influencing Trend:
Increasing Government and Non-government Initiatives i.e. DOTS to Eradicate Tuberculosis and Promising Pipeline for the Treatment of Tuberculosis.

Market Growth Drivers:
Increasing Prevalence of Tuberculosis and Government Initiatives to Control the Proliferation of Tuberculosis

Challenges:
Inability to Identify the Initial Symptoms of Tuberculosis

Restraints:
Lack of Awareness Regarding Tuberculosis in Emerging Economies and High-Cost Factor Associated With the Treatment of Tuberculosis May Hamper the Global Tuberculosis Treatment Drugs market.

Opportunities:
Extensive Awareness Campaigns and Initiatives by Various Governments to Curb the Risk of Tuberculosis

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mainly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the market's growth. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Data Sources of Tuberculosis Drug Market Study

Primary Collection: InMail, LinkedIn Groups, Survey Monkey, Google, and Other professional Forums are some of the mediums utilized to gather primary data through key industry participants and appointees, subject-matter experts, C-level executives of Tuberculosis Drug Industry, among others including independent industry consultants, experts, to obtain and verify critical qualitative commentary and opinion and quantitative statistics, to assess future market prospects.

The primary interviews and data collected as per the below protocols:
• By Designation: C-Level, D-Level, Others
• By Company Type: Tier 1, Tier 2, Tier 3

Secondary Data Sources such as Annual reports, Press releases, Analyst meetings, Conference calls, Investor presentations, Management statements, and SEC filings of Tuberculosis Drug players along with Regulatory Sites, Association, World bank, etc were used as sources secondary set of data.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Tuberculosis Drug Study Sheds Light on
— The Tuberculosis Drug Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Tuberculosis Drug industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Tuberculosis Drug industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • First-line Anti-TB Drugs
  • Second-line Anti-TB Drugs
By Application
  • Active TB
  • Latent TB
By End User
  • Hospital
  • Clinic
  • Durgstore

By Testing
  • TB skin test (TST)
  • TB blood tests
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Tuberculosis
      • 3.2.2. Government Initiatives to Control the Proliferation of Tuberculosis
    • 3.3. Market Challenges
      • 3.3.1. Inability to Identify the Initial Symptoms of Tuberculosis
    • 3.4. Market Trends
      • 3.4.1. Increasing Government and Non-government Initiatives i.e. DOTS to Eradicate Tuberculosis
      • 3.4.2. Promising Pipeline for the Treatment of Tuberculosis.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Tuberculosis Drug, by Type, Application, End User, Testing and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Tuberculosis Drug (Value)
      • 5.2.1. Global Tuberculosis Drug by: Type (Value)
        • 5.2.1.1. First-line Anti-TB Drugs
        • 5.2.1.2. Second-line Anti-TB Drugs
      • 5.2.2. Global Tuberculosis Drug by: Application (Value)
        • 5.2.2.1. Active TB
        • 5.2.2.2. Latent TB
      • 5.2.3. Global Tuberculosis Drug by: End User (Value)
        • 5.2.3.1. Hospital
        • 5.2.3.2. Clinic
        • 5.2.3.3. Durgstore
      • 5.2.4. Global Tuberculosis Drug by: Testing (Value)
        • 5.2.4.1. TB skin test (TST)
        • 5.2.4.2. TB blood tests
        • 5.2.4.3. Others
      • 5.2.5. Global Tuberculosis Drug Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Tuberculosis Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Johnson & Johnson (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Lupin Limited (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Eli Lilly and Company (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Labatec Pharma SA (Jordan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Mylan N.V (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sanofi S.A (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sandoz S.A (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novartis International AG (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Macleods Pharmaceuticals (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Otsuka Pharmaceutical Co.Ltd. (Japan)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Tuberculosis Drug Sale, by Type, Application, End User, Testing and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Tuberculosis Drug (Value)
      • 7.2.1. Global Tuberculosis Drug by: Type (Value)
        • 7.2.1.1. First-line Anti-TB Drugs
        • 7.2.1.2. Second-line Anti-TB Drugs
      • 7.2.2. Global Tuberculosis Drug by: Application (Value)
        • 7.2.2.1. Active TB
        • 7.2.2.2. Latent TB
      • 7.2.3. Global Tuberculosis Drug by: End User (Value)
        • 7.2.3.1. Hospital
        • 7.2.3.2. Clinic
        • 7.2.3.3. Durgstore
      • 7.2.4. Global Tuberculosis Drug by: Testing (Value)
        • 7.2.4.1. TB skin test (TST)
        • 7.2.4.2. TB blood tests
        • 7.2.4.3. Others
      • 7.2.5. Global Tuberculosis Drug Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Tuberculosis Drug: by Type(USD Million)
  • Table 2. Tuberculosis Drug First-line Anti-TB Drugs , by Region USD Million (2016-2021)
  • Table 3. Tuberculosis Drug Second-line Anti-TB Drugs , by Region USD Million (2016-2021)
  • Table 4. Tuberculosis Drug: by Application(USD Million)
  • Table 5. Tuberculosis Drug Active TB , by Region USD Million (2016-2021)
  • Table 6. Tuberculosis Drug Latent TB , by Region USD Million (2016-2021)
  • Table 7. Tuberculosis Drug: by End User(USD Million)
  • Table 8. Tuberculosis Drug Hospital , by Region USD Million (2016-2021)
  • Table 9. Tuberculosis Drug Clinic , by Region USD Million (2016-2021)
  • Table 10. Tuberculosis Drug Durgstore , by Region USD Million (2016-2021)
  • Table 11. Tuberculosis Drug: by Testing(USD Million)
  • Table 12. Tuberculosis Drug TB skin test (TST) , by Region USD Million (2016-2021)
  • Table 13. Tuberculosis Drug TB blood tests , by Region USD Million (2016-2021)
  • Table 14. Tuberculosis Drug Others , by Region USD Million (2016-2021)
  • Table 15. South America Tuberculosis Drug, by Country USD Million (2016-2021)
  • Table 16. South America Tuberculosis Drug, by Type USD Million (2016-2021)
  • Table 17. South America Tuberculosis Drug, by Application USD Million (2016-2021)
  • Table 18. South America Tuberculosis Drug, by End User USD Million (2016-2021)
  • Table 19. South America Tuberculosis Drug, by Testing USD Million (2016-2021)
  • Table 20. Brazil Tuberculosis Drug, by Type USD Million (2016-2021)
  • Table 21. Brazil Tuberculosis Drug, by Application USD Million (2016-2021)
  • Table 22. Brazil Tuberculosis Drug, by End User USD Million (2016-2021)
  • Table 23. Brazil Tuberculosis Drug, by Testing USD Million (2016-2021)
  • Table 24. Argentina Tuberculosis Drug, by Type USD Million (2016-2021)
  • Table 25. Argentina Tuberculosis Drug, by Application USD Million (2016-2021)
  • Table 26. Argentina Tuberculosis Drug, by End User USD Million (2016-2021)
  • Table 27. Argentina Tuberculosis Drug, by Testing USD Million (2016-2021)
  • Table 28. Rest of South America Tuberculosis Drug, by Type USD Million (2016-2021)
  • Table 29. Rest of South America Tuberculosis Drug, by Application USD Million (2016-2021)
  • Table 30. Rest of South America Tuberculosis Drug, by End User USD Million (2016-2021)
  • Table 31. Rest of South America Tuberculosis Drug, by Testing USD Million (2016-2021)
  • Table 32. Asia Pacific Tuberculosis Drug, by Country USD Million (2016-2021)
  • Table 33. Asia Pacific Tuberculosis Drug, by Type USD Million (2016-2021)
  • Table 34. Asia Pacific Tuberculosis Drug, by Application USD Million (2016-2021)
  • Table 35. Asia Pacific Tuberculosis Drug, by End User USD Million (2016-2021)
  • Table 36. Asia Pacific Tuberculosis Drug, by Testing USD Million (2016-2021)
  • Table 37. China Tuberculosis Drug, by Type USD Million (2016-2021)
  • Table 38. China Tuberculosis Drug, by Application USD Million (2016-2021)
  • Table 39. China Tuberculosis Drug, by End User USD Million (2016-2021)
  • Table 40. China Tuberculosis Drug, by Testing USD Million (2016-2021)
  • Table 41. Japan Tuberculosis Drug, by Type USD Million (2016-2021)
  • Table 42. Japan Tuberculosis Drug, by Application USD Million (2016-2021)
  • Table 43. Japan Tuberculosis Drug, by End User USD Million (2016-2021)
  • Table 44. Japan Tuberculosis Drug, by Testing USD Million (2016-2021)
  • Table 45. India Tuberculosis Drug, by Type USD Million (2016-2021)
  • Table 46. India Tuberculosis Drug, by Application USD Million (2016-2021)
  • Table 47. India Tuberculosis Drug, by End User USD Million (2016-2021)
  • Table 48. India Tuberculosis Drug, by Testing USD Million (2016-2021)
  • Table 49. South Korea Tuberculosis Drug, by Type USD Million (2016-2021)
  • Table 50. South Korea Tuberculosis Drug, by Application USD Million (2016-2021)
  • Table 51. South Korea Tuberculosis Drug, by End User USD Million (2016-2021)
  • Table 52. South Korea Tuberculosis Drug, by Testing USD Million (2016-2021)
  • Table 53. Taiwan Tuberculosis Drug, by Type USD Million (2016-2021)
  • Table 54. Taiwan Tuberculosis Drug, by Application USD Million (2016-2021)
  • Table 55. Taiwan Tuberculosis Drug, by End User USD Million (2016-2021)
  • Table 56. Taiwan Tuberculosis Drug, by Testing USD Million (2016-2021)
  • Table 57. Australia Tuberculosis Drug, by Type USD Million (2016-2021)
  • Table 58. Australia Tuberculosis Drug, by Application USD Million (2016-2021)
  • Table 59. Australia Tuberculosis Drug, by End User USD Million (2016-2021)
  • Table 60. Australia Tuberculosis Drug, by Testing USD Million (2016-2021)
  • Table 61. Rest of Asia-Pacific Tuberculosis Drug, by Type USD Million (2016-2021)
  • Table 62. Rest of Asia-Pacific Tuberculosis Drug, by Application USD Million (2016-2021)
  • Table 63. Rest of Asia-Pacific Tuberculosis Drug, by End User USD Million (2016-2021)
  • Table 64. Rest of Asia-Pacific Tuberculosis Drug, by Testing USD Million (2016-2021)
  • Table 65. Europe Tuberculosis Drug, by Country USD Million (2016-2021)
  • Table 66. Europe Tuberculosis Drug, by Type USD Million (2016-2021)
  • Table 67. Europe Tuberculosis Drug, by Application USD Million (2016-2021)
  • Table 68. Europe Tuberculosis Drug, by End User USD Million (2016-2021)
  • Table 69. Europe Tuberculosis Drug, by Testing USD Million (2016-2021)
  • Table 70. Germany Tuberculosis Drug, by Type USD Million (2016-2021)
  • Table 71. Germany Tuberculosis Drug, by Application USD Million (2016-2021)
  • Table 72. Germany Tuberculosis Drug, by End User USD Million (2016-2021)
  • Table 73. Germany Tuberculosis Drug, by Testing USD Million (2016-2021)
  • Table 74. France Tuberculosis Drug, by Type USD Million (2016-2021)
  • Table 75. France Tuberculosis Drug, by Application USD Million (2016-2021)
  • Table 76. France Tuberculosis Drug, by End User USD Million (2016-2021)
  • Table 77. France Tuberculosis Drug, by Testing USD Million (2016-2021)
  • Table 78. Italy Tuberculosis Drug, by Type USD Million (2016-2021)
  • Table 79. Italy Tuberculosis Drug, by Application USD Million (2016-2021)
  • Table 80. Italy Tuberculosis Drug, by End User USD Million (2016-2021)
  • Table 81. Italy Tuberculosis Drug, by Testing USD Million (2016-2021)
  • Table 82. United Kingdom Tuberculosis Drug, by Type USD Million (2016-2021)
  • Table 83. United Kingdom Tuberculosis Drug, by Application USD Million (2016-2021)
  • Table 84. United Kingdom Tuberculosis Drug, by End User USD Million (2016-2021)
  • Table 85. United Kingdom Tuberculosis Drug, by Testing USD Million (2016-2021)
  • Table 86. Netherlands Tuberculosis Drug, by Type USD Million (2016-2021)
  • Table 87. Netherlands Tuberculosis Drug, by Application USD Million (2016-2021)
  • Table 88. Netherlands Tuberculosis Drug, by End User USD Million (2016-2021)
  • Table 89. Netherlands Tuberculosis Drug, by Testing USD Million (2016-2021)
  • Table 90. Rest of Europe Tuberculosis Drug, by Type USD Million (2016-2021)
  • Table 91. Rest of Europe Tuberculosis Drug, by Application USD Million (2016-2021)
  • Table 92. Rest of Europe Tuberculosis Drug, by End User USD Million (2016-2021)
  • Table 93. Rest of Europe Tuberculosis Drug, by Testing USD Million (2016-2021)
  • Table 94. MEA Tuberculosis Drug, by Country USD Million (2016-2021)
  • Table 95. MEA Tuberculosis Drug, by Type USD Million (2016-2021)
  • Table 96. MEA Tuberculosis Drug, by Application USD Million (2016-2021)
  • Table 97. MEA Tuberculosis Drug, by End User USD Million (2016-2021)
  • Table 98. MEA Tuberculosis Drug, by Testing USD Million (2016-2021)
  • Table 99. Middle East Tuberculosis Drug, by Type USD Million (2016-2021)
  • Table 100. Middle East Tuberculosis Drug, by Application USD Million (2016-2021)
  • Table 101. Middle East Tuberculosis Drug, by End User USD Million (2016-2021)
  • Table 102. Middle East Tuberculosis Drug, by Testing USD Million (2016-2021)
  • Table 103. Africa Tuberculosis Drug, by Type USD Million (2016-2021)
  • Table 104. Africa Tuberculosis Drug, by Application USD Million (2016-2021)
  • Table 105. Africa Tuberculosis Drug, by End User USD Million (2016-2021)
  • Table 106. Africa Tuberculosis Drug, by Testing USD Million (2016-2021)
  • Table 107. North America Tuberculosis Drug, by Country USD Million (2016-2021)
  • Table 108. North America Tuberculosis Drug, by Type USD Million (2016-2021)
  • Table 109. North America Tuberculosis Drug, by Application USD Million (2016-2021)
  • Table 110. North America Tuberculosis Drug, by End User USD Million (2016-2021)
  • Table 111. North America Tuberculosis Drug, by Testing USD Million (2016-2021)
  • Table 112. United States Tuberculosis Drug, by Type USD Million (2016-2021)
  • Table 113. United States Tuberculosis Drug, by Application USD Million (2016-2021)
  • Table 114. United States Tuberculosis Drug, by End User USD Million (2016-2021)
  • Table 115. United States Tuberculosis Drug, by Testing USD Million (2016-2021)
  • Table 116. Canada Tuberculosis Drug, by Type USD Million (2016-2021)
  • Table 117. Canada Tuberculosis Drug, by Application USD Million (2016-2021)
  • Table 118. Canada Tuberculosis Drug, by End User USD Million (2016-2021)
  • Table 119. Canada Tuberculosis Drug, by Testing USD Million (2016-2021)
  • Table 120. Mexico Tuberculosis Drug, by Type USD Million (2016-2021)
  • Table 121. Mexico Tuberculosis Drug, by Application USD Million (2016-2021)
  • Table 122. Mexico Tuberculosis Drug, by End User USD Million (2016-2021)
  • Table 123. Mexico Tuberculosis Drug, by Testing USD Million (2016-2021)
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Tuberculosis Drug: by Type(USD Million)
  • Table 136. Tuberculosis Drug First-line Anti-TB Drugs , by Region USD Million (2022-2027)
  • Table 137. Tuberculosis Drug Second-line Anti-TB Drugs , by Region USD Million (2022-2027)
  • Table 138. Tuberculosis Drug: by Application(USD Million)
  • Table 139. Tuberculosis Drug Active TB , by Region USD Million (2022-2027)
  • Table 140. Tuberculosis Drug Latent TB , by Region USD Million (2022-2027)
  • Table 141. Tuberculosis Drug: by End User(USD Million)
  • Table 142. Tuberculosis Drug Hospital , by Region USD Million (2022-2027)
  • Table 143. Tuberculosis Drug Clinic , by Region USD Million (2022-2027)
  • Table 144. Tuberculosis Drug Durgstore , by Region USD Million (2022-2027)
  • Table 145. Tuberculosis Drug: by Testing(USD Million)
  • Table 146. Tuberculosis Drug TB skin test (TST) , by Region USD Million (2022-2027)
  • Table 147. Tuberculosis Drug TB blood tests , by Region USD Million (2022-2027)
  • Table 148. Tuberculosis Drug Others , by Region USD Million (2022-2027)
  • Table 149. South America Tuberculosis Drug, by Country USD Million (2022-2027)
  • Table 150. South America Tuberculosis Drug, by Type USD Million (2022-2027)
  • Table 151. South America Tuberculosis Drug, by Application USD Million (2022-2027)
  • Table 152. South America Tuberculosis Drug, by End User USD Million (2022-2027)
  • Table 153. South America Tuberculosis Drug, by Testing USD Million (2022-2027)
  • Table 154. Brazil Tuberculosis Drug, by Type USD Million (2022-2027)
  • Table 155. Brazil Tuberculosis Drug, by Application USD Million (2022-2027)
  • Table 156. Brazil Tuberculosis Drug, by End User USD Million (2022-2027)
  • Table 157. Brazil Tuberculosis Drug, by Testing USD Million (2022-2027)
  • Table 158. Argentina Tuberculosis Drug, by Type USD Million (2022-2027)
  • Table 159. Argentina Tuberculosis Drug, by Application USD Million (2022-2027)
  • Table 160. Argentina Tuberculosis Drug, by End User USD Million (2022-2027)
  • Table 161. Argentina Tuberculosis Drug, by Testing USD Million (2022-2027)
  • Table 162. Rest of South America Tuberculosis Drug, by Type USD Million (2022-2027)
  • Table 163. Rest of South America Tuberculosis Drug, by Application USD Million (2022-2027)
  • Table 164. Rest of South America Tuberculosis Drug, by End User USD Million (2022-2027)
  • Table 165. Rest of South America Tuberculosis Drug, by Testing USD Million (2022-2027)
  • Table 166. Asia Pacific Tuberculosis Drug, by Country USD Million (2022-2027)
  • Table 167. Asia Pacific Tuberculosis Drug, by Type USD Million (2022-2027)
  • Table 168. Asia Pacific Tuberculosis Drug, by Application USD Million (2022-2027)
  • Table 169. Asia Pacific Tuberculosis Drug, by End User USD Million (2022-2027)
  • Table 170. Asia Pacific Tuberculosis Drug, by Testing USD Million (2022-2027)
  • Table 171. China Tuberculosis Drug, by Type USD Million (2022-2027)
  • Table 172. China Tuberculosis Drug, by Application USD Million (2022-2027)
  • Table 173. China Tuberculosis Drug, by End User USD Million (2022-2027)
  • Table 174. China Tuberculosis Drug, by Testing USD Million (2022-2027)
  • Table 175. Japan Tuberculosis Drug, by Type USD Million (2022-2027)
  • Table 176. Japan Tuberculosis Drug, by Application USD Million (2022-2027)
  • Table 177. Japan Tuberculosis Drug, by End User USD Million (2022-2027)
  • Table 178. Japan Tuberculosis Drug, by Testing USD Million (2022-2027)
  • Table 179. India Tuberculosis Drug, by Type USD Million (2022-2027)
  • Table 180. India Tuberculosis Drug, by Application USD Million (2022-2027)
  • Table 181. India Tuberculosis Drug, by End User USD Million (2022-2027)
  • Table 182. India Tuberculosis Drug, by Testing USD Million (2022-2027)
  • Table 183. South Korea Tuberculosis Drug, by Type USD Million (2022-2027)
  • Table 184. South Korea Tuberculosis Drug, by Application USD Million (2022-2027)
  • Table 185. South Korea Tuberculosis Drug, by End User USD Million (2022-2027)
  • Table 186. South Korea Tuberculosis Drug, by Testing USD Million (2022-2027)
  • Table 187. Taiwan Tuberculosis Drug, by Type USD Million (2022-2027)
  • Table 188. Taiwan Tuberculosis Drug, by Application USD Million (2022-2027)
  • Table 189. Taiwan Tuberculosis Drug, by End User USD Million (2022-2027)
  • Table 190. Taiwan Tuberculosis Drug, by Testing USD Million (2022-2027)
  • Table 191. Australia Tuberculosis Drug, by Type USD Million (2022-2027)
  • Table 192. Australia Tuberculosis Drug, by Application USD Million (2022-2027)
  • Table 193. Australia Tuberculosis Drug, by End User USD Million (2022-2027)
  • Table 194. Australia Tuberculosis Drug, by Testing USD Million (2022-2027)
  • Table 195. Rest of Asia-Pacific Tuberculosis Drug, by Type USD Million (2022-2027)
  • Table 196. Rest of Asia-Pacific Tuberculosis Drug, by Application USD Million (2022-2027)
  • Table 197. Rest of Asia-Pacific Tuberculosis Drug, by End User USD Million (2022-2027)
  • Table 198. Rest of Asia-Pacific Tuberculosis Drug, by Testing USD Million (2022-2027)
  • Table 199. Europe Tuberculosis Drug, by Country USD Million (2022-2027)
  • Table 200. Europe Tuberculosis Drug, by Type USD Million (2022-2027)
  • Table 201. Europe Tuberculosis Drug, by Application USD Million (2022-2027)
  • Table 202. Europe Tuberculosis Drug, by End User USD Million (2022-2027)
  • Table 203. Europe Tuberculosis Drug, by Testing USD Million (2022-2027)
  • Table 204. Germany Tuberculosis Drug, by Type USD Million (2022-2027)
  • Table 205. Germany Tuberculosis Drug, by Application USD Million (2022-2027)
  • Table 206. Germany Tuberculosis Drug, by End User USD Million (2022-2027)
  • Table 207. Germany Tuberculosis Drug, by Testing USD Million (2022-2027)
  • Table 208. France Tuberculosis Drug, by Type USD Million (2022-2027)
  • Table 209. France Tuberculosis Drug, by Application USD Million (2022-2027)
  • Table 210. France Tuberculosis Drug, by End User USD Million (2022-2027)
  • Table 211. France Tuberculosis Drug, by Testing USD Million (2022-2027)
  • Table 212. Italy Tuberculosis Drug, by Type USD Million (2022-2027)
  • Table 213. Italy Tuberculosis Drug, by Application USD Million (2022-2027)
  • Table 214. Italy Tuberculosis Drug, by End User USD Million (2022-2027)
  • Table 215. Italy Tuberculosis Drug, by Testing USD Million (2022-2027)
  • Table 216. United Kingdom Tuberculosis Drug, by Type USD Million (2022-2027)
  • Table 217. United Kingdom Tuberculosis Drug, by Application USD Million (2022-2027)
  • Table 218. United Kingdom Tuberculosis Drug, by End User USD Million (2022-2027)
  • Table 219. United Kingdom Tuberculosis Drug, by Testing USD Million (2022-2027)
  • Table 220. Netherlands Tuberculosis Drug, by Type USD Million (2022-2027)
  • Table 221. Netherlands Tuberculosis Drug, by Application USD Million (2022-2027)
  • Table 222. Netherlands Tuberculosis Drug, by End User USD Million (2022-2027)
  • Table 223. Netherlands Tuberculosis Drug, by Testing USD Million (2022-2027)
  • Table 224. Rest of Europe Tuberculosis Drug, by Type USD Million (2022-2027)
  • Table 225. Rest of Europe Tuberculosis Drug, by Application USD Million (2022-2027)
  • Table 226. Rest of Europe Tuberculosis Drug, by End User USD Million (2022-2027)
  • Table 227. Rest of Europe Tuberculosis Drug, by Testing USD Million (2022-2027)
  • Table 228. MEA Tuberculosis Drug, by Country USD Million (2022-2027)
  • Table 229. MEA Tuberculosis Drug, by Type USD Million (2022-2027)
  • Table 230. MEA Tuberculosis Drug, by Application USD Million (2022-2027)
  • Table 231. MEA Tuberculosis Drug, by End User USD Million (2022-2027)
  • Table 232. MEA Tuberculosis Drug, by Testing USD Million (2022-2027)
  • Table 233. Middle East Tuberculosis Drug, by Type USD Million (2022-2027)
  • Table 234. Middle East Tuberculosis Drug, by Application USD Million (2022-2027)
  • Table 235. Middle East Tuberculosis Drug, by End User USD Million (2022-2027)
  • Table 236. Middle East Tuberculosis Drug, by Testing USD Million (2022-2027)
  • Table 237. Africa Tuberculosis Drug, by Type USD Million (2022-2027)
  • Table 238. Africa Tuberculosis Drug, by Application USD Million (2022-2027)
  • Table 239. Africa Tuberculosis Drug, by End User USD Million (2022-2027)
  • Table 240. Africa Tuberculosis Drug, by Testing USD Million (2022-2027)
  • Table 241. North America Tuberculosis Drug, by Country USD Million (2022-2027)
  • Table 242. North America Tuberculosis Drug, by Type USD Million (2022-2027)
  • Table 243. North America Tuberculosis Drug, by Application USD Million (2022-2027)
  • Table 244. North America Tuberculosis Drug, by End User USD Million (2022-2027)
  • Table 245. North America Tuberculosis Drug, by Testing USD Million (2022-2027)
  • Table 246. United States Tuberculosis Drug, by Type USD Million (2022-2027)
  • Table 247. United States Tuberculosis Drug, by Application USD Million (2022-2027)
  • Table 248. United States Tuberculosis Drug, by End User USD Million (2022-2027)
  • Table 249. United States Tuberculosis Drug, by Testing USD Million (2022-2027)
  • Table 250. Canada Tuberculosis Drug, by Type USD Million (2022-2027)
  • Table 251. Canada Tuberculosis Drug, by Application USD Million (2022-2027)
  • Table 252. Canada Tuberculosis Drug, by End User USD Million (2022-2027)
  • Table 253. Canada Tuberculosis Drug, by Testing USD Million (2022-2027)
  • Table 254. Mexico Tuberculosis Drug, by Type USD Million (2022-2027)
  • Table 255. Mexico Tuberculosis Drug, by Application USD Million (2022-2027)
  • Table 256. Mexico Tuberculosis Drug, by End User USD Million (2022-2027)
  • Table 257. Mexico Tuberculosis Drug, by Testing USD Million (2022-2027)
  • Table 258. Research Programs/Design for This Report
  • Table 259. Key Data Information from Secondary Sources
  • Table 260. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Tuberculosis Drug: by Type USD Million (2016-2021)
  • Figure 5. Global Tuberculosis Drug: by Application USD Million (2016-2021)
  • Figure 6. Global Tuberculosis Drug: by End User USD Million (2016-2021)
  • Figure 7. Global Tuberculosis Drug: by Testing USD Million (2016-2021)
  • Figure 8. South America Tuberculosis Drug Share (%), by Country
  • Figure 9. Asia Pacific Tuberculosis Drug Share (%), by Country
  • Figure 10. Europe Tuberculosis Drug Share (%), by Country
  • Figure 11. MEA Tuberculosis Drug Share (%), by Country
  • Figure 12. North America Tuberculosis Drug Share (%), by Country
  • Figure 13. Global Tuberculosis Drug share by Players 2021 (%)
  • Figure 14. Global Tuberculosis Drug share by Players (Top 3) 2021(%)
  • Figure 15. Global Tuberculosis Drug share by Players (Top 5) 2021(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 18. Johnson & Johnson (United States) Revenue: by Geography 2021
  • Figure 19. Lupin Limited (India) Revenue, Net Income and Gross profit
  • Figure 20. Lupin Limited (India) Revenue: by Geography 2021
  • Figure 21. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Pfizer Inc. (United States) Revenue: by Geography 2021
  • Figure 23. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 24. Eli Lilly and Company (United States) Revenue: by Geography 2021
  • Figure 25. Labatec Pharma SA (Jordan) Revenue, Net Income and Gross profit
  • Figure 26. Labatec Pharma SA (Jordan) Revenue: by Geography 2021
  • Figure 27. Mylan N.V (United States) Revenue, Net Income and Gross profit
  • Figure 28. Mylan N.V (United States) Revenue: by Geography 2021
  • Figure 29. Sanofi S.A (France) Revenue, Net Income and Gross profit
  • Figure 30. Sanofi S.A (France) Revenue: by Geography 2021
  • Figure 31. Sandoz S.A (Germany) Revenue, Net Income and Gross profit
  • Figure 32. Sandoz S.A (Germany) Revenue: by Geography 2021
  • Figure 33. Novartis International AG (India) Revenue, Net Income and Gross profit
  • Figure 34. Novartis International AG (India) Revenue: by Geography 2021
  • Figure 35. Macleods Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 36. Macleods Pharmaceuticals (India) Revenue: by Geography 2021
  • Figure 37. Otsuka Pharmaceutical Co.Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 38. Otsuka Pharmaceutical Co.Ltd. (Japan) Revenue: by Geography 2021
  • Figure 39. Global Tuberculosis Drug: by Type USD Million (2022-2027)
  • Figure 40. Global Tuberculosis Drug: by Application USD Million (2022-2027)
  • Figure 41. Global Tuberculosis Drug: by End User USD Million (2022-2027)
  • Figure 42. Global Tuberculosis Drug: by Testing USD Million (2022-2027)
  • Figure 43. South America Tuberculosis Drug Share (%), by Country
  • Figure 44. Asia Pacific Tuberculosis Drug Share (%), by Country
  • Figure 45. Europe Tuberculosis Drug Share (%), by Country
  • Figure 46. MEA Tuberculosis Drug Share (%), by Country
  • Figure 47. North America Tuberculosis Drug Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Johnson & Johnson (United States)
  • Lupin Limited (India)
  • Pfizer Inc. (United States)
  • Eli Lilly and Company (United States)
  • Labatec Pharma SA (Jordan)
  • Mylan N.V (United States)
  • Sanofi S.A (France)
  • Sandoz S.A (Germany)
  • Novartis International AG (India)
  • Macleods Pharmaceuticals (India)
  • Otsuka Pharmaceutical Co.Ltd. (Japan)
Select User Access Type

Key Highlights of Report


Jan 2021 232 Pages 91 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Tuberculosis Drug Quantitative research analysis
Tuberculosis Drug Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2017-2021; Base year: 2021; Forecast period: 2022 to 2027
Companies that are profiled in Global Tuberculosis Drug Market are Johnson & Johnson (United States), Lupin Limited (India), Pfizer Inc. (United States), Eli Lilly and Company (United States), Labatec Pharma SA (Jordan), Mylan N.V (United States), Sanofi S.A (France), Sandoz S.A (Germany), Novartis International AG (India), Macleods Pharmaceuticals (India) and Otsuka Pharmaceutical Co.Ltd. (Japan) etc.
Active TB segment in Global market to hold robust market share owing to "Increasing Prevalence of Tuberculosis ".
AMA Research predicts that United States Players will contribute to the maximum growth of Global Tuberculosis Drug market throughout the forecasted period.

Know More About Tuberculosis Drug Report?

Have a Query? Click Here

Other Related Reports

Inflammatory Bowel Disease Comprehensive Study by Type (Anti-inflammatory Biologics, Non-Steroidal Anti-inflammatory drugs (NSAIDs), Corticosteroids), Application (Hospital, Drugs Stores), Route of A...
$ 3450
Organ Transplant Immunosuppressant Drugs Comprehensive Study by Type (Chemical Composition, Fungal Product, Biologics), Application (Liver Transplant, Kidney Transplant, Other Organ Transplant), Drug...
$ 3650
Tissue Engineering Comprehensive Study by Type (Synthetic Materials, Biologically Derived Materials, Others), Application (Orthopedics, Musculoskeletal & Spine, Neurology, Cardiology & Vascular, Skin...
$ 3450
Autoimmune Disease Therapeutics Comprehensive Study by Indication (Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease, Others), Distribution Channel (Hospitals, Clinic...
$ 3750
Impingement Syndrome Comprehensive Study by Type (Structural Impingement, Functional Impingement), Application (Hospitals, Physical Therapists), Treatment (Physical Therapy, Medications (Aspirin, Nap...
$ 3750
Blood Plasma Derivatives Comprehensive Study by Type (Albumin, Anti-Thrombin III, Intravenous Immunoglobulin (IVIG), Fresh Frozen Plasma (FFP), Others), Application (Hemophilia A, Hemophilia B, HIV, ...
$ 3750